FDA “Consumer Updates” To Get Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Agency’s Risk Communications and Advisory Committee is holding a two-day meeting to discuss how to better target FDA communications.
You may also be interested in...
Risk Communication Advisory Committee suggests that adding the agency imprimatur to REMS materials may help distinguish it from promotional mail and ensure providers read the communications.
Proposed pilot program would look for the best patient counseling practices, but can FDA remind providers to discuss a drug’s benefits without actually specifying them?
Company reluctantly agrees to FDA’s request to suspend sales of ponatinib due to serious thrombotic risks while a narrower label and Risk Evaluation and Mitigation Strategy are negotiated. FDA cites serious adverse vascular event rates of 48% and 24% in Phase I and II ponatinib trials, respectively.